Therapeutic area intelligence for Kidney Cancer with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

oncology therapeutics →

Assets

Pazopanib →

POU2F2 →

Recent signals(3)

ClinicalJuly 10, 2026

POU2F2 identified as a key oncogenic and immunomodulatory factor in kidney cancer

POU2F2 is upregulated in kidney renal clear cell carcinoma and correlates with poor prognosis and macrophage polarization.

ClinicalJuly 10, 2026

FT-IR Spectroscopy Identifies Non-Invasive Biomarkers for Kidney Cancer Detection

FT-IR spectral analysis of urine and serum reveals biomarkers correlating with kidney cancer histological grade.

ClinicalJune 25, 2026

Phase III Trial of Pazopanib in Metastatic Kidney Cancer Post-Surgery

A phase III trial is evaluating the efficacy of pazopanib hydrochloride versus placebo in patients with metastatic kidney cancer post-surgery.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Kidney Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.